Pneumonia vaccine beneficial, CDC says
This chart provides a simple way to answer questions that pharmacists will receive this winter. Winter is almost here, and a typical phone call to the pharmacy will likely involve questions about antibiotics to treat pneumonia. When doctors call, it is usually because the patient has multiple dru...
from 35 studies reported from 16 countries in Western Europe which found that serotype 14 was the most common in a patient population aged <18 years, ranging from 19% to 47%.23 This strain is included in Prevnar, a heptavalent pneumococcal conjugate vaccine (PCV7) approved by the FDA in ...
Polysaccha- ride conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015;372(12):1114–25. 10. Cinotti R, Dordonnat-Moynard A, Feuillet F, Roquilly A, Rondeau N, Lepel- letier D, Caillon J, Asseray N, Blanloeil Y, Rozec B, et al. Risk factors and ...
However, there is no vaccine or effective antiviral treatment against the newly emerged coronavirus and identifying the available therapeutics as soon as possible is critical for the response to the spread of SARS-CoV-2. Shufeng Jiedu Capsule (SFJDC), a well-known prescription of Traditional ...
A Centers for Disease Control and Prevention (CDC) committee has recommended Prevnar 13 [Pneumococcal 13-valent Conjugate Vaccine] for routine use to help protect adults aged 65 years and older against pneumococcal disease, Pfizer announced.M. LoweryAdvanstar Communications Inc...
Swine Flu Tied to Rise in Pneumonias Among Young; On more positive note, CDC sees few signs of trouble with the H1N1 vaccine.(Centers for Disease Control and Prevention)(Report)Reinberg, Steven
Delivery inside nasal cavity of pneumonia micrococcus polysaccharide vaccineThe invention relates to a method for preventing against diseases induced by Streptococcus pneumoniae infections, which comprises mucosally administering to a patient in need a S. pneumoniae capsular polysaccharide. This latter may ...
(IQR: 24 years). At least one comorbidity was present in 84.8% (n= 1653) of patients. At admission, 76.1% of patients had complicated pneumonia. Pneumococcus was identified in 34.9% (n= 680) of study participants. The PCV20 vaccine-type CAP occurred in 23.9% (n= 465) of all ...
The post-acute sequelae of SARS-CoV-2 (PASC) pose a threat to patients’ health-related quality of life (HRQOL). Here, the impact of COVID-19 on HRQOL and the clinical factors associated with impaired HRQOL were examined. Discharged COVID-19 patients wer